• Alnylam published a medical research presentation on ALN-6400, an investigational RNAi therapy designed to lower liver-expressed plasminogen to reduce bleeding.
• Program positioned for rare bleeding disorders, prioritizing hereditary hemorrhagic telangiectasia and von Willebrand disease; company estimates about 5 million people live with bleeding disorders globally.
• Materials cite proof of mechanism in healthy volunteers; Phase 1 healthy-volunteer data, initial Phase 2 HHT results targeted for 2H26.
• Strategy centers on infrequent subcutaneous dosing, four injections per year, to support prophylactic bleeding control.
• Presentation highlights data suggesting plasminogen lowering is not expected to raise thrombotic risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein.